Voriconazole serum levels measured by high-performance liquid chromatography: A monocentric study in treated patients

Medical Mycology

Volumn 50, Issue 4, 2012, Pages 439-445

  Gómez López, Alicia ^a   Cendejas Bueno, Emilio ^a   Cuesta, Isabel ^a   Rodríguez, Julio García ^b   Rodríguez Tudela, Juan L ^a   Gutierrez Altes A ^b   Cuenca Estrella, Manuel ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Outcome; Ravuconazole; Trough voriconazole levels

Indexed keywords

VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ARTHRITIS; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG MONITORING; DRUG TREATMENT FAILURE; FEMALE; FUNGAL ENDOCARDITIS; FUSARIOSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIMIT OF QUANTITATION; LUNG ASPERGILLOSIS; LUNG INFECTION; MALE; PRESCHOOL CHILD; PROSTHESIS INFECTION; PSEUDALLESCHERIASIS; RETROSPECTIVE STUDY; SCHOOL CHILD; ULTRAVIOLET RADIATION; WOUND INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOSES; PYRIMIDINES; RETROSPECTIVE STUDIES; SERUM; TIME FACTORS; TRIAZOLES; YOUNG ADULT;

EID: 84859770329     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2011.630039     Document Type: Article

References (29)

1. Walsh TJ, Anaissie EJ, Denning DW, et al . Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46 : 327-360. (Pubitemid 351265310)
2. Pappas PG, Kauffman CA, Andes D, et al . Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48 : 503-535.
3. Boyd AE, Modi S, Howard SJ, e t al . Adverse reactions to voriconazole. Clin Infect Dis 2004; 39 : 1241-1244. (Pubitemid 40169325)
4. Denning DW, Ribaud P, Milpied N, e t al . Effi cacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34 : 563-571. (Pubitemid 34165316)
5. Imhof A, Schaer DJ, Schanz U, Schwarz U. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly 2006; 136 : 739-742. (Pubitemid 46032197)
6. Pascual A, Calandra T, Bolay S, et al . Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves effi cacy and safety outcomes. Clin Infect Dis 2008; 46 : 201-211. (Pubitemid 351269158)
7. Smith J, Safdar N, Knasinski V, et al . Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50 : 1570-1572.
8. Trifi lio S, Ortiz R, Pennick G, et al . Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005; 35 : 509-513. (Pubitemid 40403355)
9. Miyakis S, van Hal SJ, Ray J, Marriott D. Voriconazole concentrations and outcome of invasive fungal infections. Clin Microbiol Infect 2009; 16 : 957-933.
10. Potoski BA, Brown J. The safety of voriconazole. C lin Infect Dis 2002; 35 : 1273-1275.
11. Drusano GL. How does a patient maximally benefi t from anti-infective chemotherapy? Clin Infect Dis 2004; 39 : 1245-1246. (Pubitemid 40169326)
12. Trifi lio S, Singhal S, Williams S, et al . Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2006; 40 : 451-456.
13. Hope WW, Billaud EM, Lestner J, Denning DW. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis 2008; 21 : 580-586.
14. Smith J, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit 2008; 30 : 167-172. (Pubitemid 351521643)
15. Segal BH, Herbrecht R, Stevens DA, e t al . Defi ning responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008; 47 : 674-683.
16. Food and Drug Administration (FDA). Guidance for Industry, Bioanalytical Method Validation 2001. Available from the website: http:// www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM070107.pdf
17. Shah VP, Midha KK, Findlay JW, et al . Bioanalytical method validation - a revisit with a decade of progress. Pharm Res 2000; 17 : 1551-1557. (Pubitemid 32217566)
18. European Medicines Agency (EMEA). Vfend: summary of product characteristics, 2009. Available from the website: http://www.ema. europa.eu/ema/index.jsp?curl- pages/medicines/human/medicines/
19. Trifi lio SM, Yarnold PR, Scheetz MH, et al . Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation. Antimicrob Agents Chemother 2009; 53 : 1793-1796.
20. Walsh TJ, Driscoll T, Milligan PA, et al . Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother 2010; 54 : 4116-4123.
21. Berge M, Guillemain R, Boussaud V, e t al . Voriconazole pharmacokinetic variability in cystic fi brosis lung transplant patients. Transpl Infect Dis 2009; 11 : 211-219.
22. Trifi lio S, Pennick G, Pi J, e t al . Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007; 109 : 1532-1535. (Pubitemid 46595688)
23. Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis 2010; 50 : 27-36.
24. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fl uid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003; 37 : 728-732. (Pubitemid 37100817)
25. Chhun S, Rey E, Tran A, et al . Simultaneous quantifi cation of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 852 : 223-228. (Pubitemid 46839210)
26. Keevil BG, Newman S, Lockhart S, e t al . Validation of an assay for voriconazole in serum samples using liquid chromatography-tandem mass spectrometry. Ther Drug Monit 2004; 26 : 650-657. (Pubitemid 39579147)
27. Langman LJ, Boakye-Agyeman F. Measurement of voriconazole in serum and plasma. Clin Biochem 2007; 40 : 1378-1385. (Pubitemid 350151419)
28. Prajapati AM, Patel SA, Patel NJ, Patel DB, Patel SK. Development and validation of reversed-phase column high-performance liquid chromatographic and fi rst-derivative UV spectrophotometric methods for estimation of voriconazole in oral suspension powder. J AOAC Int 2008; 91 : 1070-1074.
29. Vogeser M, Schiel X, Spohrer U. Quantifi cation of voriconazole in plasma by liquid chromatography-tandem mass spectrometry. Clin Chem Lab Med 2005; 43 : 730-734. (Pubitemid 41461178)